The Global Health Body Issues Alert Over Critical Scarcity of Obesity Injections
Less than 10% of individuals who could benefit from GLP-1 drugs like Wegovy are able to get them, states the WHO as it issues its inaugural guidance on the medications.
Given more than one billion individuals worldwide now obese, it is urging broader and more equitable availability to these injectable treatments.
Based on estimates, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"Our latest guidance affirms that obesity is a chronic disease that can be addressed with holistic and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are key barriers to broad access to the treatments that can aid individuals in losing substantial weight, explains the body.
Skinny Jab Shortage
Despite the current most optimistic outlook, the production of GLP-1 therapies would only suffice for approximately 100 million people – less than 10% of eligible patients, according to the health organization.
The guideline encourages countries and companies to widen availability, via approaches such as licensing agreements.
The intellectual property rights on the active ingredient – the primary component of Novo Nordisk's Wegovy – is set to lapse in multiple countries in 2026.
The Way Obesity Jabs Function
These medications mimick a biological compound to delay gastric emptying, reduce hunger and increase feelings of fullness so individuals consume fewer calories.
Patients typically see weight reduction within a few weeks of starting on the weekly injections.
Evidence indicates users may see weight return after a year of halting the drug, when their normal hunger return.
Being above a healthy weight raises your risk for experiencing medical conditions, such as diabetes, cardiovascular issues, stroke, and certain cancers.
Obesity concerns people in all nations and was associated with 3.7 million fatalities worldwide in 2024, as per the WHO.
